Showing results (71-80 of 117) with videos related to
Sort By:
Pageof 12
Multiple Sclerosis and Related Disorders|December 6, 2024
Effect of alemtuzumab on fatigue, quality of life, and patient/caregiver-reported outcomes in relapsing-remitting multiple sclerosis-A real-world evidence studyJette Lautrup Frederiksen, Luca Massacesi, Helle Hvilsted Nielsen, et al.Journal of Neurology, Neurosurgery, and Psychiatry|June 15, 2025
Multiple sclerosis from onset to secondary progression: a 30-year Italian register studyAurora Zanghì, Massimiliano Copetti, Carlo Avolio, et al.Journal of Neurology|January 3, 2024
Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS RegistryLorena Lorefice, Ottavia Elena Ferraro, Giuseppe Fenu, et al.Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 2, 2021
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS RegisterEmanuele D'Amico, Aurora Zanghì, Marzia Romeo, et al.Journal of Neurology|September 28, 2018
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyLuca Prosperini, Pietro Annovazzi, Laura Boffa, et al.Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|April 12, 2021
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison StudyAurora Zanghì, Antonio Gallo, Carlo Avolio, et al.Journal of Neurology|June 8, 2020
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysisEmanuele D'Amico, Aurora Zanghì, Mariangela Sciandra, et al.Journal of Clinical Medicine|April 23, 2022
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter StudyRoberta Lanzillo, Antonio Carotenuto, Elisabetta Signoriello, et al.Journal of Neurology|August 23, 2024
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimodAntonio Carotenuto, Cristina Di Monaco, Laura Papetti, et al.Journal of Neurology|August 23, 2024
Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosisMarta Simone, Giuseppe Lucisano, Tommaso Guerra, et al.Pageof 12